Wound complications after bevacizumab treatment in patients operated on for ovarian cancer.
The aim of this study was to report and analyze the rate of wound complications in patients treated for ovarian cancer with or without adjuvant bevacizumab.


METHODS
Were included in a prospective cohort study, all the patients with advanced ovarian cancer who received adjuvant chemotherapy with or without bevacizumab in our center from April 2007 to January 2009. The patients were separated into a bevacizumab adjuvant therapy group (n=13) and a control group without bevacizumab (n=12). All the patients underwent upfront surgery and received standard chemotherapy (carboplatin with paclitaxel). The patients were examined every two months by a gynecological surgeon and underwent abdomino pelvic CT-scan regularly.


RESULTS
Among the 25 patients included in the study, six experienced wound dehiscence (24%). Five out of these six patients had received bevacizumab in addition to standard chemotherapy (p=0.078).


CONCLUSIONS
We report a high rate of wound complications in ovarian cancer patients receiving bevacizumab after surgery.
Department of Obstetrics and Gynecology, Hospital Tenon,Assistance Publique des Hôpitaux de Paris, CancerEst, University Pierre et Marie Curie Paris 6, France. martin.koskas@wanadoo.fr
Martin
M
Koskas
Elisabeth
E
Chereau
Marcos
M
Ballester
Frederic
F
Selle
Roman
R
Rouzier
Emile
E
Daraï
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000601:surgery; D011379:Prognosis; D011446:Prospective Studies; D013529:Surgical Wound Dehiscence / Q000139:chemically induced*; D015996:Survival Rate
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab